Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MAP2 | P11137 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890768 | 0.89 | PDE4B (0.45) | ACLYCYP2C19SIRT1 | |
| SCHEMBL9890727 | 0.87 | FFAR1 (0.49) | PTGDR2FFAR1FFAR4ACLYCYP2C19 | |
| SCHEMBL5429296 | 0.87 | PTGDR2 (0.56) | PTGDR2FFAR1FFAR4ACLYHPGD | |
| SCHEMBL30084999 | 0.83 | RECQL (0.43) | ACLYCYP2C19TP53HPGDBACE1 | |
| SCHEMBL7311559 | 0.81 | BCAT2 (0.50) | ACLYCYP2C19 | |
| SCHEMBL2394999 | 0.81 | ICMT (0.46) | FFAR1FFAR4ACLYMAP2 | |
| SCHEMBL9890724 | 0.81 | PTGDR2 (0.50) | PTGDR2ACLYHPGD | |
| SCHEMBL2394194 | 0.80 | L3MBTL1 (0.46) | PTGDR2CYP2C19TP53SIRT1 | |
| SCHEMBL2393525 | 0.80 | PTGDR2 (0.47) | PTGDR2FFAR1FFAR4HPGDSHMT1 | |
| SCHEMBL6184923 | 0.80 | CYP2C19 (0.64) | PTGDR2FFAR1FFAR4ACLYCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| WO-2010055911-A1 | BIPHENYLACETAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGDR2 1062/4885FFAR1 223/4885FFAR4 621/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGDR2 1062/4885FFAR1 223/4885FFAR4 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.